Novartis India Surges 25.79% Weekly Despite Strong Sell Downgrade

Novartis India Ltd delivered a remarkable weekly gain of 25.79%, closing at Rs.996.50 on 20 Feb 2026, significantly outperforming the Sensex despite receiving a Strong Sell downgrade citing valuation and financial concerns. The stock's dramatic rally contrasted sharply with fundamental warnings issued mid-week.

The stock began the week on 16 Feb 2026 opening at Rs.825.15, a 4.16% increase from the previous close of Rs.792.20, outpacing the Sensex's 0.70% gain. Volume of 147,863 shares traded indicated solid participation. On 17 Feb 2026, the stock price remained largely flat, inching up by 0.05% to Rs.825.60 on very low volume of 5,698 shares. The stock regained momentum on 18 Feb 2026, climbing 2.90% to close at Rs.849.55 with volume increasing to 18,160 shares.

A Strong Sell rating was issued on 19 Feb 2026, with the company's Mojo Score dropping to 28.0. The downgrade highlighted expensive valuation multiples, including a P/E ratio of 21.57 and a PEG ratio of 1.70, alongside a 36.8% decline in quarterly profit after tax and a 7.63% contraction in net sales. The stock price reacted negatively, falling 2.25% to Rs.830.45 on a volume of 9,854 shares, underperforming the Sensex's 1.45% decline.

Despite the downgrade, the stock staged a remarkable recovery on 20 Feb 2026, opening with a strong gap up of 8.86% and closing at Rs.996.50, a 20.00% gain on the day. The stock reached an intraday high of Rs.977.95, surging 16.37% intraday and outperforming the Sensex's 0.41% gain. Volume surged dramatically to 1,034,421 shares, signalling robust buying interest. The stock traded above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating strong technical momentum.

The stock opened at a price reflecting a 5.47% premium over its prior closing value on the final trading day, reaching an intraday high of Rs.1,074, marking a 7.78% increase from the previous close. The stock outperformed its sector by 2.08% that day, while the Sensex index recorded a more modest gain of 0.75%.

Over the past month, the stock delivered a 29.87% return compared to the Sensex's 2.33% gain in the same period. The stock's cumulative increase over the last two trading days reached 22.82%, reflecting sustained investor confidence.

Technical indicators presented a mixed picture. The Moving Average Convergence Divergence (MACD) is mildly bullish on a weekly basis, though it shows mild bearishness monthly. The Relative Strength Index (RSI) remains bearish on both weekly and monthly charts. Bollinger Bands indicate bullish trends on weekly and monthly timeframes. The Know Sure Thing (KST) indicator is mildly bullish weekly but bearish monthly, while Dow Theory assessments are mildly bullish across both weekly and monthly periods. Daily moving averages present a mildly bearish stance.

Novartis India Ltd is classified as a high beta stock, with an adjusted beta of 1.35 relative to the Small and Mid Cap (SMLCAP) index. This elevated beta suggests that the stock is more volatile than the broader market, typically experiencing larger price swings in both directions.

Despite deteriorating quarterly financial results, the company maintained a robust ROCE of 60.87%. The dividend yield stood at 3.01%. Long-term operating profit growth reached an annualised 57.68%. The Market Cap Grade stands at 3, indicating a moderate market capitalisation relative to peers.

The parent company Novartis Inc. traded on the SIX Swiss Exchange at 130.50 CHF, up 2.40 or 1.87% at close, with delayed pricing. The stock showed a 1 Month Return of 14.19%, 3 Months Return of 24.90%, 6 Months Return of 29.00%, and 1 Year Return of 33.63%. Volume reached 5.86M shares.